Novartis: positive data for Enerzair Breezhaler

(CercleFinance.com) - Novartis announces that, according to a post-hoc analysis, its Enerzair Breezhaler in high doses and once daily, significantly reduces the rates of moderate-to-severe and severe asthma exacerbation rates in some patients, compared to a medium dose.


This analysis, based on data from the pivotal phase III IRIDIUM study and presented at the European Respiratory Society (ERS) International Congress 2020, also shows a safety profile consistent with previous studies, the Swiss Health Group says.


Copyright (c) 2020 CercleFinance.com. All rights reserved.